Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation – Study 2 (waiting list)
2023-506436-33-00Phase 3Completed
- Sponsor
- Bellvitge University Hospital
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dulaglutide in cardiometabolic risk (CMR) and prediabetes, sponsored by Bellvitge University Hospital. Primary endpoint: Reversal of metabolic syndrome at 3 and 6 months. Started Dec 2023; status: completed.
02
Drugs
dulaglutide
03
Conditions
cardiometabolic risk (CMR)prediabetes
Beyond the preview
Go deeper on 2023-506436-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506436-33-00.